



- (51) **International Patent Classification:**
C07K 16/38 (2006.01)
- (21) **International Application Number:**
PCT/US2014/050896
- (22) **International Filing Date:**
13 August 2014 (13.08.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/865,451 13 August 2013 (13.08.2013) US
14305757.8 22 May 2014 (22.05.2014) EP
- (71) **Applicant:** SANOFI [FR/FR]; 54, rue La Boétie, F-75008 Paris (FR).
- (72) **Inventors; and**
- (71) **Applicants :** PRITSKER, Alla [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). GRAILHE, Patrick [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). RAK, Alexey [DE/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). MATHIEU, Magali [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). MORGAN, Christopher Ryan [US/US]; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, NJ 08807 (US). BAURIN, Nicolas [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). POIRER, Bruno [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). DAVEU, Cyril [FR/FR]; 5 rue Dupont des Loges, F-75007 Paris (FR). DUFFIEUX, Francis [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR). LI, Han [US/US]; 388 Twig Lane, Yardley, PA 19067 (US). KOMINOS, Dorothea [US/US]; 99 Rolling Hill Drive, Millington, NJ 07946 (US). JANIAK, Philip [FR/FR]; c/o Sanofi, 54, rue La Boétie, F-75008 Paris (FR).
- (74) **Agent:** DEGIULIO, James V.; McDonnell Boehnen Hulbert & Berghoff LLP, 300 South Wacker Drive, Suite 3100, Chicago, IL 60606 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
- Declarations under Rule 4.17:**
- *of inventorship (Rule 4.17(iv))*
- Published:**
- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(54) **Title:** ANTIBODIES TO PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) AND USES THEREOF

(57) **Abstract:** The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1). The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either *in vitro* or *in vivo*, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

